Table 2. Summary of screening results of new polyomavirus from both laboratories.
| Virus name | PML | HIV-positive | MS | Other Immunosuppressed | Hepatitis C Virus-positive | ONS | Result source | |
| HIV-positive | HIV-negative | |||||||
| KIPyV | 0/50 | 0/30 | 0/36 | 0/115 | 0/36 | N/A | 0/2 | Laboratory 1 |
| 0/50 | 0/30 | 0/36 | 0/2 | 0/36 | N/A | 0/2 | Laboratory 2 | |
| WUPyV | 0/50 | 0/30 | 0/36 | 0/115 | 0/36 | N/A | 0/2 | Laboratory 1 |
| 0/50 | 0/30 | 0/36 | 0/2 | 0/36 | N/A | 0/2 | Laboratory 2 | |
| MCPyV | 0/50 | 0/30 | 0/36 | 0/115 | 0/36 | N/A | 0/2 | Laboratory 1 |
| 0/50 | 0/30 | 0/36 | 0/2 | 1/36 (2.8%) | N/A | 0/2 | Laboratory 2 | |
Total: 269 samples from 123 patients.
PML: progressive multifocal leukoencephalopathy; ONS: other neurological syndromes; N/A: specimens not available; MS: multiple sclerosis; KIPyV: KI polyomavirus; WUPyV: WU polyomavirus; MCPyV: Merckel cell carcinoma polyomavirus.